Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prevest DenproBOM:543363 +2.81%85 Return-on-Tangible-Equity is 18.67% as of Mar. 2026, which is 34% below its 10-year median of 28.30. GuruFocus rates BOM:543363 with a GF Score™ of 85/100 and a GF Value™ of ₹623.61 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Prevest Denpro ranks better than 81% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Prevest Denpro's annualized net income for the quarter that ended in Mar. 2026 was ₹232.9 Mil. Prevest Denpro's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹1,247.0 Mil. Therefore, Prevest Denpro's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 18.67%.
The historical rank and industry rank for Prevest Denpro's Return-on-Tangible-Equity or its related term are showing as below:
BOM:543363'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 17.78 Med: 28.3 Max: 39.13
Current: 17.78
During the past 8 years, Prevest Denpro's highest Return-on-Tangible-Equity was 39.13%. The lowest was 17.78%. And the median was 28.30%.
BOM:543363's Return-on-Tangible-Equity is ranked better than 81% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs BOM:543363: 17.78
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Prevest Denpro Return-on-Tangible-Equity Related Terms
Prevest Denpro Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Prevest Denpro's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543363 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Prevest Denpro's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prevest Denpro Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prevest Denpro's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Prevest Denpro's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.67% mean?
Prevest Denpro (BOM:543363) has a Return-on-Tangible-Equity of 18.67% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Prevest Denpro and its competitors. This is 34% below median its historical median of 28.30. Over the past decade, Prevest Denpro's Return-on-Tangible-Equity has ranged from 17.78 to 39.13. According to the industry distribution chart, Prevest Denpro ranks #144 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 19%.
Is Prevest Denpro's Return-on-Tangible-Equity too high?
Prevest Denpro's current Return-on-Tangible-Equity of 18.67% is 34% below median its 10-year median of 28.30. Over the past 10 years, this metric has ranged from a low of 17.78 to a high of 39.13. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Prevest Denpro's value of 18.67% is 360.4% above this industry median. Based on the distribution chart, Prevest Denpro ranks #144 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Prevest Denpro has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Prevest Denpro's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prevest Denpro ranks #144 out of 758 companies for Return-on-Tangible-Equity. This places Prevest Denpro in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.06. Prevest Denpro's value of 18.67% is 360.4% above this benchmark. Historically, Prevest Denpro's own Return-on-Tangible-Equity has ranged from 17.78 to 39.13 over the past decade. While the company's 10-year median is 28.30 vs. the industry median of 4.06, Prevest Denpro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prevest Denpro's current Return-on-Tangible-Equity of 18.67% is 360.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Prevest Denpro and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prevest Denpro's current Return-on-Tangible-Equity is 18.67%, which is 34% below median its own 10-year median of 28.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prevest Denpro stock overvalued right now?
Based on GuruFocus' analysis, Prevest Denpro (BOM:543363) is currently considered Possible Value Trap. The stock's GF Value™ is ₹623.61, compared to a current price of ₹402.00 — trading 35.5% below its estimated fair value. The current Return-on-Tangible-Equity is 18.67%, which is 34% below median its 10-year median of 28.30 and 360.4% above the Medical Devices & Instruments industry median of 4.06. Prevest Denpro's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Prevest Denpro (BOM:543363), the current Return-on-Tangible-Equity is 18.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prevest Denpro (BOM:543363) Overvalued in 2026?
Based on GuruFocus' analysis, Prevest Denpro stock appears to be undervalued.
The current stock price of ₹402.00 is trading 35.5% below its estimated GF Value™ of ₹623.61.
GuruFocus considers Prevest Denpro to be Possible Value Trap.
Key valuation signals for BOM:543363:
Return-on-Tangible-Equity: 18.67% (34% below median its 10-year median of 28.30)
GF Value™: ₹623.61 vs. price of ₹402.00 (35.5% below fair value)
Industry Position: 360.4% above the Medical Devices & Instruments median (#144 of 758)
No single metric tells the full story. See the BOM:543363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prevest Denpro Ltd develops, manufactures and markets a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The company's product portfolio covers wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables.
85GF Score
Get the complete analysis for BOM:543363
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543363 has been successfully added to your 
